SCHEMBL6350076

SCHEMBL6350076

c1cncc(N2CCCCNCC2)c1

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 8/20 0.91
CHRNA4 P43681 8/20 0.91
ALDH1A1 P00352 1/20 0.52
ADRB2 P07550 1/20 0.51
NCF1 P14598 1/20 0.51
PLD1 Q13393 1/20 0.51
CHRNA1 P02708 2/20 0.51
CHRNA7 P36544 2/20 0.51
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
ADRB1 P08588 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
CHRNG P07510 1/20 0.49
CHRNB1 P11230 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRND Q07001 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3061045 0.95 CHRNB2 (1.00) CHRNB2CHRNA4ALDH1A1ADRB2NCF1
SCHEMBL3065598 0.92 CHRNB2 (0.94) CHRNB2CHRNA4ALDH1A1CHRNA1CHRNA7
SCHEMBL5655866 0.92 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA1CHRNA7CHRNG
SCHEMBL29507540 0.92 CHRNB2 (0.87) CHRNB2CHRNA4ALDH1A1ADRB2NCF1
SCHEMBL5335 0.92 CHRNB2 (0.87) CHRNB2CHRNA4ALDH1A1ADRB2NCF1
SCHEMBL3538787 0.92 CHRNB2 (0.87) CHRNB2CHRNA4ALDH1A1ADRB2NCF1
Hydrochloric Acid SCHEMBL9066315 0.90 CHRNB2 (0.84) CHRNB2CHRNA4ALDH1A1ADRB2NCF1
SCHEMBL161236 0.86 CHRNB2 (0.76) CHRNB2CHRNA4CHRNA1CHRNA7CHRNG
SCHEMBL29959593 0.86 CHRNB2 (0.76) CHRNB2CHRNA4CHRNA1CHRNA7CHRNG
SCHEMBL1462348 0.84 CHRNB2 (0.73) CHRNB2CHRNA4ALDH1A1CHRNA1CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 EP disclosed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 CHRNB2 700/4885CHRNA4 1019/4885ALDH1A1 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.